Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
FamiCord AG is a leading European company specializing in the collection, processing, cryopreservation, and storage of stem cells from umbilical cord blood, cord tissue, and postnatal tissues. Headquartered in Leipzig, Germany, and founded in 1997 as Vita 34 AG, it rebranded to FamiCord AG in February 2025 following mergers with entities like Polish PBKM, forming Europe's largest stem cell bank with over 1,000,000 stored units. Operating through segments such as Vita 34 and PBKM, the company serves families across Germany, Poland, Portugal, and internationally, including expansions to Dubai, the UK, Middle East, and Asia. FamiCord AG develops advanced therapies, including CAR-T cells and viral vectors for cancer treatment, genetic tests, and biobanking services like sperm freezing and adipose tissue storage. It partners with over 1,500 clinics, enabling more than 8,000 patient treatments and 260 cord blood transplantations, while providing biotech solutions in regenerative medicine. With 771 employees, FamiCord AG plays a pivotal role in the healthcare sector, bridging stem cell preservation with innovative cellular therapies.
The business is unprofitable at the operating level (-2.72% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 7.3%, steady but not accelerating.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
€88M
▲ +7.3% YoY
Net Income (TTM)
-€6M
▲ +45.4% YoY
Op. Margin
-3.09%
▲ +10.0pp YoY
ROIC
-6.31%
▲ +15.6pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow
N/A
Net Debt
€13M
Cash & Equiv.
€10M
3Y CAGR: +8.5%
3Y CAGR: +126.7%
Continue Research